You are here

  • Home
  • Online First
  • Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Article Text

Article menu

other Versions

Download PDFPDF

Miscellaneous
Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Free

https://doi.org/10.1136/ijgc-2019-001012corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Mayadev J, Zamarin D, Deng W, et al. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer 2019. doi: 10.1136/ijgc-2019-001012.

    Since the online publication of this article, the authors have noticed that their funding statement incorrectly states 'The authors have not declared a specific grant for this research from anyfunding agency in the public, commercial or not-for-profit sectors'. The correct funding statement is ‘This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office, NRG Oncology Statistics and Data Management Center (U10 CA180822) and NRG Oncology Operations Center (U10CA180868)’